Five Prime Therapeutics (FPRX) Sees Windfall on Anti-CSF1R Collaboration Agreement (BMY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Oppenheimer Raises Price Target Following Five Prime Therapeutics' (FPRX) Announced Licensing Agreement with BMY
October 19, 2015 6:42 AM EDTOppenheimer reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX), and raised the price target to $48.00 (from $45.00), following the company's Oct. 15th announcement of a licensing agreement for FPA008 with BMY. FPRX will receive $350M cash upfront and is eligible for an additional $1.39B in development/regulatory... More
Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY
October 15, 2015 4:06 PM EDTLeerink Partners reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX) following an announced exclusive $1.74Bn license and collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) for the development and commercialization of FPRXs CSF1R antibody... More
Five Prime Therapeutics (FPRX) Enters Collaboration with Bristol-Myers Squibb (BMY) Worth Up to $1.74B
October 15, 2015 6:06 AM EDTBristol-Myers Squibb Company (NYSE: BMY) and Five Prime Therapeutics, Inc.(Nasdaq: FPRX) today announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Primes colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications. This agreement replaces the companies existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibbs programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumor... More
